Fig. 5.
S117A-FGF2 prevents Dox-induced ROS accumulation and oxidation of phosphatidylcholines. Neonatal rat cardiomyocytes were treated with Dox in the presence and absence of S117A-FGF-2 pre-treatment. a The effect of S117A-FGF2 on Dox-induced Dox upregulation as measured by the DCF-DA assay. b–d Levels of oxidized phosphatidylcholine species (HODA-PPC (PLPC); PAPC (–OOH); SLPC (–OH, –OOH)) measured by LC/MS/MS and normalized for protein concentration. The Y-axis in panels b–d shows the amount (ng) of OxPC per μg cardiomyocyte protein. In all panels, brackets denote groups significantly different from each other (n = 3 independent analyses)